Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
Open Access
- 1 October 2019
- journal article
- review article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 13, 1655-1666
Abstract
Dimethyl fumarate (DMF) is an oral disease-modifying therapy approved for management of relapsing-remitting multiple sclerosis patients. Results from phase 3 clinical trials (DEFINE, CONFIRM) and follow-up study (ENDORSE) have provided good evidence for its efficacy and safety profile. Patient-reported outcomes (PROs) assessment revealed stabilization or boost in health-related quality of life and work productivity of patients treated with DMF compared to placebo reflecting a higher patient satisfaction to therapy. Being an oral agent with relatively favorable risk versus benefit profile DMF is commonly prescribed first-line agent. However, literature suggests that intolerance to side effects, especially gastrointestinal adverse effects and flushing is one of the major causes to compromised therapeutic compliance. An increase in the real-world incidence of progressive multifocal leukoencephalopathy and liver abnormality cases is also concerning. Several prevention and mitigation strategies like patient counseling, dose up-titration, pretreatment with aspirin, use of symptomatic therapy and frequent blood monitoring have demonstrated to be effective in tackling these adverse effects and promoting adherence to DMF. In this article, we review the efficacy, safety, PROs and patient adhere data, along with various measures to manage adverse events and promote compliance.Keywords
This publication has 62 references indexed in Scilit:
- Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort studyBMC Neurology, 2013
- Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysisPatient Preference and Adherence, 2013
- Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)Health Services Insights, 2013
- Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) SignalingJournal of Biological Chemistry, 2012
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cellsJournal of Experimental Medicine, 2011
- The Anti-Inflammatory Effects of Dimethyl Fumarate in Astrocytes Involve Glutathione and Haem Oxygenase-1ASN Neuro, 2011
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Pharmacokinetics of oral fumarates in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- Dimethylfumarate Is a Potent Inducer of Apoptosis in Human T CellsJournal of Investigative Dermatology, 2003
- Regulatory Mechanisms Controlling Gene Expression Mediated by the Antioxidant Response ElementAnnual Review of Pharmacology and Toxicology, 2003